LY320135 is a selective cannabinoid (CB) receptor 1 antagonist (Ks = 224 and >10,000 nM for CB and CB, respectively, in vitro). It is selective for CB over α- and α- adrenergic, D and D dopamine, benzodiazepine, histamine H, GABA, serotonin (5-HT), and muscarinic receptors. It reverses the inhibition of forskolin-induced cAMP accumulation induced by arachidonoyl ethanolamide (anandamide; ) in CHO cells and inhibits a stimulatory effect of arachidonoyl ethanolamide on adenylate cyclase induced by application of pertussis toxin (IC = 734 nM). LY320135 (1 mg/kg) reverses inhibition of light-induced phase shifts in hamsters induced by the CB agonist CP 55,940 .
LY320135 is a potent and selective antagonist of CB1 receptor, with a Ki of 141 nM. LY320135 also binds to 5-HT2 and muscarinic receptors with Kis of 6.4 μM and 2.1 μM, respectively. LY320135 exhibits neuroprotective effect.
体外研究
LY320135 has a relatively low affinity for the CB2 receptor (Ki=14.9±0.4 μM) and ten other unrelated receptors.
LY320135 (1 nM-10 μM) inhibits the anandamide-mediated forskolin-stimulated cAMP accumulation in CHO cell, with an IC50 of 734±122 nM.
LY320135 (0.1-1000 nM; 1-8 min) can reverse calcium current (ICa) inhibition by WIN 55212-2 in N18 cells, with an IC50 of 55±10 nM.
LY320135 (1 μM) prevents activation of Kir current by WIN 55212-2 in AtT-20-CB1 cells.
LY 320135 (0.001-1 μM) reduces CA1 injury induced by 20 min oxygen-glucose deprivation (OGD) in a concentration-dependent manner.
分子式
C24H17NO4
分子量
383.4
CAS号
176977-56-3
中文名称
4-[[6-甲氧基-2-(4-甲氧基苯基)-3-苯并呋喃]羰基]苯甲腈
运输条件
Room temperature in continental US; may vary elsewhere.